Table 2 Clinical backgrounds of the IS group
From: Eicosapentaenoic Acid as long-term secondary prevention after ischemic stroke
Asymptomatic | BI-no recurrence | BI-recurrence | p value | |
|---|---|---|---|---|
N | 13 | 42 | 6 | |
Sex (F/M) | 8/5 | 13/29 | 3/3 | 0.122 |
Age | 72.1 ± 11.7 | 68.4 ± 12.7 | 76.5 ± 9.9 | 0.262 |
EPA (mg) | 2077 ± 432 | 1907 ± 407 | 1650 ± 677 | 0.151 |
Length (years) | 4.7 ± 4.2 | 3.9 ± 4.2 | 7.3 ± 5.4 | 0.200 |
Hypertension (%) | 76.9 | 71.4 | 66.7 | 0.883 |
Hyperlipidemia (%) | 83.3 | 85.0 | 100 | 0.500 |
DM (%) | 75.0 | 42.9 | 33.3 | 0.191 |
Af (%) | 7.7 | 9.5 | 16.6 | 0.824 |
TCho (mg/dl) | 190.7 ± 46.8 | 170.3 ± 32.5 | 201.8 ± 28.2 | 0.054 |
LDL (mg/dl) | 114.7 ± 39.7 | 96.9 ± 27.0 | 120.5 ± 43.2 | 0.088 |
TG (mg/dl) | 140.8 ± 69.3 | 119.6 ± 53.5 | 248.5 ± 325.9 | 0.046 |
Cre (mg/dl) | 0.7 ± 0.2 | 0.7 ± 0.2 | 1.1 ± 0.5 | 0.001 |
eGFR (ml/min/1.73 m2) | 74.5 ± 18.8 | 85.0 ± 21.9 | 52.7 ± 23.3 | 0.008 |
AP, single (%) | 7.7 | 45.2 | 50.0 | 0.041 |
AP, multi (%) | 0 | 19.0 | 16.7 | 0.096 |
Warfarin (%) | 7.7 | 7.1 | 0 | 0.536 |
W + AP (%) | 0 | 4.8 | 0 | 0.490 |
None (%) | 84.6 | 21.4 | 16.7 | 0.001 |